Botswana Vaccine Institute

The Botswana Vaccine Institute (BVI) is a government-owned veterinary research and vaccine manufacturing institution based in Gaborone, Botswana. Its work is centered on communicable diseases affecting domestic animals, particularly viral infections that threaten cattle and other livestock. The institute combines laboratory research, vaccine development, manufacturing, quality-related activities, and international supply, making it an important part of Botswana’s animal-health and livestock-support infrastructure. BVI was founded in 1978 and was registered the following year as Botswana Vaccine Institute Limited, a self-funding company wholly owned by the Government of Botswana. Its institutional role has therefore combined public ownership with a commercial operating model. The organization was established in the context of Botswana’s need to protect livestock, an economically and socially significant sector, from diseases that can cause animal losses, restrict trade, and disrupt regional food and agricultural systems. The institute initially concentrated on vaccines for foot-and-mouth disease (FMD), one of the most consequential transboundary livestock diseases in southern Africa. Over time, its research and manufacturing portfolio expanded to include vaccines associated with anthrax, contagious bovine pleuropneumonia, ovine rinderpest, black quarter disease, and rabies. The breadth of this portfolio reflects BVI’s broader mandate: not simply producing one vaccine, but maintaining capabilities relevant to several major veterinary disease threats. BVI is also described as an international reference laboratory for FMD. This gives the institute a role beyond domestic vaccine supply, including specialized scientific capacity related to disease identification, surveillance, and technical support. Its products are used in Botswana and sold in 16 countries across Africa and the Middle East, providing the institution with a regional rather than exclusively national footprint. The institute developed a partnership with Merial, the French pharmaceutical group, beginning with cooperation related to FMD vaccines. The partnership formed part of BVI’s effort to strengthen its technical and production capabilities while remaining a Botswana-owned institution. The available reference material does not specify the partnership’s full legal structure, duration, or current status. BVI’s headquarters and main offices are located in Broadhurst Industrial Park in Gaborone. In February 2024, the institute began collaborating with Uganda’s Ministry of Agriculture, Animal Industry and Fisheries on a type-specific FMD vaccine intended for Uganda. The stated purpose was to improve control of the disease and help prevent future outbreaks by developing a vaccine suited to local requirements. This initiative illustrates BVI’s continuing role as a regional veterinary-biologicals partner. As a brand, BVI is positioned around scientific competence, livestock protection, national veterinary capacity, and regional disease control. It is not primarily a consumer-facing brand; its principal audiences are government veterinary services, livestock producers, animal-health authorities, research institutions, and international public-sector or commercial partners. Public information in the supplied references is limited regarding current leadership, detailed product names, production volumes, financial performance, and the institute’s present organizational structure. Those fields are therefore left unspecified rather than inferred.

The Botswana Vaccine Institute emerged in 1978 as part of Botswana’s effort to build domestic capacity for veterinary disease research and vaccine production. Livestock health has long been strategically important to Botswana, and infectious animal diseases can affect herd survival, agricultural livelihoods, government veterinary programs, and access to regional and international markets. Establishing a specialized institution enabled the country to address these risks through local scientific and manufacturing capabilities rather than relying entirely on external suppliers. In 1979, the institution was registered as Botswana Vaccine Institute Limited. Although wholly owned by the Government of Botswana, it was structured as a self-funding company. This arrangement combined public-sector ownership with an operating model intended to support the organization’s own activities through the production and sale of veterinary vaccines and related services. The supplied reference material does not identify the precise governance arrangements or financing mechanisms beyond this description. The institute’s early emphasis was foot-and-mouth disease. FMD is a highly contagious disease affecting cloven-hoofed animals and is a major concern for cattle-producing countries because outbreaks can lead to animal-health emergencies, movement restrictions, trade disruption, and substantial economic losses. BVI subsequently became associated with the research and manufacture of FMD vaccines and developed additional expertise in laboratory work related to the disease. It is described as an international reference laboratory for FMD, indicating a specialized role in the wider animal-health system beyond routine production. Over the course of its development, BVI diversified its veterinary-biologicals portfolio. The diseases identified in the available material include anthrax, contagious bovine pleuropneumonia, ovine rinderpest, black quarter disease, and rabies. This expansion broadened the institute’s relevance across cattle, sheep, and other domestic-animal health programs. The reference material does not provide launch dates, formulations, brand names, or production quantities for these individual vaccine lines. BVI also established a partnership with Merial, a French pharmaceutical group. The cooperation began with FMD vaccines and formed part of the institute’s development as a technically capable producer with a regional role. The available sources do not explain the partnership’s contractual terms, ownership implications, or present status, so it is best understood as a historical technical or commercial relationship rather than evidence of a current parent company. The institute’s customer and stakeholder base extends beyond Botswana. Its vaccines are used domestically and sold in 16 African and Middle Eastern countries. This export activity gives BVI a role in regional veterinary supply chains and reflects the cross-border nature of livestock diseases. Its public identity consequently combines national institution-building with international animal-health service provision. BVI is headquartered in Broadhurst Industrial Park on Lejara Road in Gaborone. Its facilities there house the institute’s main offices and central institutional operations. The supplied material does not provide a detailed account of laboratory buildings, manufacturing platforms, regulatory approvals, or workforce composition. In February 2024, BVI began working with Uganda’s Ministry of Agriculture, Animal Industry and Fisheries on a type-specific FMD vaccine suited to Uganda. The collaboration was framed around disease control and prevention of future outbreaks. It demonstrates the institute’s continuing willingness to adapt its vaccine work to country-specific epidemiological needs and to cooperate with national veterinary authorities outside Botswana. BVI remains an active, government-owned veterinary research and manufacturing institution. Its historical development can be summarized as a progression from a Botswana-focused FMD capability to a broader livestock-vaccine organization with reference-laboratory functions, international sales, and regional technical partnerships. Publicly available information in the supplied sources is insufficient to document current executives, annual financial results, detailed product specifications, or recent corporate restructuring.

• 2024

  Uganda vaccine collaboration

  [1]Botswana Vaccine Instituteen.wikipedia.org

  BVI began collaborating with Uganda’s agriculture ministry on a type-specific foot-and-mouth disease vaccine for use in Uganda.

• 1979

  Registered as Botswana Vaccine Institute Limited

  [1]Botswana Vaccine Instituteen.wikipedia.org

  The institution was registered as a self-funding company wholly owned by the Government of Botswana.

• 1978

  Institute founded

  [1]Botswana Vaccine Instituteen.wikipedia.org

  The Botswana Vaccine Institute was founded to support veterinary research and vaccine production for livestock disease control in Botswana.

• Expansion beyond foot-and-mouth disease

  [1]Botswana Vaccine Instituteen.wikipedia.org

  BVI broadened its research and manufacturing activities to include vaccines associated with anthrax, contagious bovine pleuropneumonia, ovine rinderpest, black quarter disease, and rabies.

• Partnership with Merial

  [1]Botswana Vaccine Instituteen.wikipedia.org

  BVI formed a partnership with Merial, initially involving foot-and-mouth disease vaccines.

A Botswana-owned veterinary research and vaccine manufacturing institution focused on protecting livestock, supporting national animal-health programs, and supplying vaccines to African and Middle Eastern markets.

• Veterinary vaccine

  Foot-and-mouth disease vaccines

  Foot-and-mouth disease vaccines are BVI’s principal and historically foundational product area. The institute began with FMD vaccine work and is also described as an international reference laboratory for the disease. Its FMD activities support Botswana’s livestock-health programs and overseas supply, while the 2024 Uganda collaboration focused on developing a type-specific formulation suited to Ugandan disease-control needs.

• Veterinary vaccine

  Anthrax vaccines

  BVI’s stated portfolio includes vaccines against anthrax, a serious bacterial disease affecting livestock and capable of creating public-health concerns. The supplied reference identifies anthrax as one of the diseases addressed by the institute but does not specify the product’s launch date, formulation, or current availability.

• Veterinary vaccine

  Contagious bovine pleuropneumonia vaccines

  The institute has diversified into vaccines for contagious bovine pleuropneumonia, an important cattle disease. This line is consistent with BVI’s livestock-protection mandate and regional focus, although the supplied material does not provide detailed product specifications or current distribution information.

• Veterinary vaccine

  Ovine rinderpest vaccines

  Ovine rinderpest is listed among the diseases for which BVI has conducted vaccine research and manufacture. No further information is supplied about the product’s chronology, regulatory status, or present commercial position.

• Veterinary vaccine

  Black quarter disease vaccines

  BVI’s portfolio includes vaccine work addressing black quarter disease, a livestock infection relevant to cattle health. The available reference does not identify a separate product brand, launch date, or current sales status.

• Veterinary vaccine

  Rabies vaccines

  Rabies vaccine work is included among BVI’s areas of diversification. The supplied sources do not state which animal species are covered, whether the line remains in production, or how it is distributed.

• 2024

  Develop a Uganda-specific type of foot-and-mouth disease vaccineProduct launch

  Background

  Uganda and BVI sought to improve control of foot-and-mouth disease and reduce the likelihood of future outbreaks with a vaccine type suited to Uganda.

  Action taken

  BVI began collaboration with Uganda’s Ministry of Agriculture, Animal Industry and Fisheries on a type-specific FMD vaccine.

  Aftermath

  The supplied material confirms the start of the collaboration but does not report a completed product, approval, production volume, or measurable outcome.

  Source

1. 1Botswana Vaccine Instituteen.wikipedia.org